Table 1.
Baseline characteristics of the study population.
| Variables | Statistics |
|---|---|
| Sex | |
| Female (%) Male (%) |
31 (59.6%) 21 (40.4%) |
| Therapy (%) | |
| Sofosbuvir/Velpatasvir | 9 (17.3%) |
| Ledipasvir/Sofosbuvir | 20 (38.5%) |
| Glecaprevir/Pibrentasvir | 17 (32.7%) |
| Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir | 6 (11.5%) |
| Duration (weeks) = 8 (%) | 28 (53.8%) |
| Naive/Experienced = N (%) | 46 (88.5%) |
| Fibrosis (Fibromax) (%) | |
| F0 | 3 (5.8%) |
| F1 | 5 (9.6%) |
| F1–F2 | 11 (21.2%) |
| F2 | 4 (7.7%) |
| F3 | 11 (21.2%) |
| F4 | 18 (34.6%) |
| Age (mean (SD)) | 62.44 (10.07) |
| BMI (%) | |
| Mildly Underweight | 2 (3.8%) |
| Normal Weight | 21 (40.4%) |
| Overweight | 13 (25%) |
| Obesity Class I | 15 (28.8%) |
| Obesity Class II | 1 (1.9%) |
| Environment = U (%) | 33 (63.5%) |
| Fibroscan (mean (SD)) | 8.36 (3.48) |